Direct detection and quantitation of DNA and protein biomarkers without enzymatic amplification
Vialogy reports that it has been awarded two key patents: US patent 6,780,589 which describes use of ViaLogy's quantum resonance interferometry (QRI) for repeatable ultra-weak signal amplification in dynamic noise backgrounds, and US patent 6,704,662 which describes techniques for quantitating biological markers in complex genomic and proteomic samples.
QRI enables amplification and analysis of digital output patterns in information only rather than in physical matter or energy. "We are pleased to have been issued theses patents which further strengthen our intellectual property and technology portfolio," said Douglas Lane, CEO and President of ViaLogy. "The technologies described in the patents enable synthetic amplification of extremely low level DNA signals without the cost, time, materials and expertise needed for chemical or enzymatic amplification".
Currently microarray users can improve data quality for their gene expression or RNA transcript profiling by using Vialogy's VMAxST on-line service to process images from Affymetrix scanners, amongst others.
Vialogy anticipates that the new capabilities afforded by these two new patents will open new research, development, clinical and diagnostic applications for microarrays by enabling high fidelity, highly sensitive and reproducible gene expression profiling from very small sample sizes and smaller sets of samples.
ViaLogy users seek robust direct detection using RNA harvested from 10 to 100 cells obtained using laser capture micro-dissection (LCM) on a variety of expression platforms. ViaLogy has previously been issued four US patents on its QRI technology for biomarker, microarray and biochip analysis including diagnostic applications with nucleic acids, proteins and viral load.
